Sarepta Therapeutics, Inc.
SRPT · Nasdaq
SRPT · Nasdaq
The supplied evidence identifies Sarepta Therapeutics as a biotechnology and pharmaceutical company, but it does not specify the products it sells, therapeutic areas, commercial segments, customer groups, geographic footprint, or employee scale. The financial figures show that the company generated $1.9 billion of revenue in fiscal 2025, up from $1.8 billion in fiscal 2024, while net income changed from a $0.2 billion profit to a $0.7 billion loss. No segment-level revenue, product contribution, or customer concentration data is provided, so the company’s operating mix and present commercial scale cannot be described further without adding unsupported information.
